# US 2023/0406838 A1 · Mutant selective egfr inhibitors and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406838 A1
- Document ID: US20230406838A1
- Status: Published application
- Kind: A1
- Application number: 18/189,092
- Filed: 2023-03-23
- Published: 2023-12-21
- Earliest claimed: 2020-09-25
- Assignees: Dana-Farber Cancer Institute, Inc.
- Applicants: Dana-Farber Cancer Institute, Inc.
- Inventors: David Heppner; Michael Eck; Stefan Laufer; Florian Wittlinger; Marcel Guenther
- Web page: https://patentgrep.com/patent/US20230406838A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 35/00: Antineoplastic agents
- C07D 233/84: Sulfur atoms
- C07D 401/14: containing three or more hetero rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure relates to compounds that act as inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof;
wherein:
Z is C or S═O;
Y is selected from the group consisting of NH, C1-C6 alkyl, C6-C10 aryl, 5-10 membered heteroaryl, C3-C10 cycloalkyl, and 3-10 membered heterocycloalkyl;
alternatively, Z═O and Y are absent;
A is 5-10 membered heteroaryl containing at least one nitrogen atom;
alternatively, A and NHR2 are absent;
B is selected from the group consisting of C6-C10 aryl, 5-10 membered heteroaryl, C3-C10 cycloalkyl, 3-10 membered heterocycloalkyl, and 5-10 membered bicyclic ring;
R1 is C1-C6 alkyl;
R2 is H, CO(C1-C6 alkyl), or C6-C10 aryl, wherein aryl is optionally substituted one or two times with R5;
R3 is selected from the group consisting of H, halo, CN, OH, NH2, and CF3;
each R4 is independently selected from the group consisting of H, OH, halo, C1-C6alkyl, C1-C6alkoxy, C6-C10 aryl, 5-10 membered heteroaryl, CH2-(5-10 membered bicyclic ring), and CH2NHC(O)(C6-C10 aryl), wherein aryl is optionally independently substituted one, two, or three times with halo, CO2H, or C1-C6 haloalkyl;
each R5 is independently selected from the group consisting of halo, OH, C1-C6 alkoxy, and NHC(O)C2-C6 alkenyl and
R6 is H or C1-C6 alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein A is pyridine; and B is phenyl, thiophene, or dihydro-indene.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is C1-C3 alkyl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R2 is CO(C1-C3 alkyl) or phenyl, wherein phenyl is optionally substituted one or two times with R5.

### Claim 6 (depends on 1)

The compound of claim 1, wherein Z is C.

### Claim 7 (depends on 1)

The compound of claim 1, wherein Z is S═O.

### Claim 8 (depends on 1)

The compound of claim 1, wherein Y is selected from the group consisting of NH, C1-C3 alkyl, phenyl, naphthalene, pyridine, indole, thiophene, furan, C3-C5 cycloalkyl, and 3-5 membered heterocycloalkyl.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R3 is H or halo.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The compound of claim 1 wherein each R4 is independently selected from the group consisting of H, OH, halo, C1-C3 alkyl, C1-C3 alkoxy, phenyl, thiophene, indole, CH2-(5-10 membered bicyclic ring), and CH2NHC(O)phenyl, wherein phenyl is optionally substituted one, two, or three times with halo, CO2H, or C1-C3 haloalkyl.

### Claim 12 (depends on 11)

The compound of claim 11, wherein each R4 is independently selected from the group consisting of H, OH, halo, C1-C3 alkyl, C1-C3 alkoxy, phenyl, thiophene, indole,
wherein phenyl is optionally substituted with halo, CO2H, or C1-C3 haloalkyl.

### Claim 13 (depends on 1)

The compound of claim 1 wherein R6 is H.

### Claim 14 (depends on 1)

The compound of claim 1 wherein the compound of Formula I is a compound of Formula IIa or Formula IIb:
or a pharmaceutically acceptable salt thereof.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The compound of claim 1, wherein the compound of Formula I is a compound of Formula III:
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

The compound of claim 1, wherein the compound of Formula I is a compound of Formula IV:
or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

The compound of claim 1, wherein the compound of Formula I is selected from the group consisting of
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

The compound of claim 1, wherein
Z is C or S═O;
Y is selected from the group consisting of NH, C1-C3 alkyl, phenyl, naphthalene, pyridine, indole, thiophene, furan, C1-C5 cycloalkyl, and 3-5 membered heterocycloalkyl;
A is pyridine;
B is phenyl, thiophene, or dihydro-indene;
R1 is C1-C3 alkyl;
R2 is CO(C1-C3 alkyl) or phenyl, wherein phenyl is optionally substituted one or two times with R5;
R3 is H or halo;
each R4 is independently selected from the group consisting of H, OH, halo, C1-C3 alkyl, C1-C3 alkoxy, phenyl, thiophene, indole, CH2-(5-10 membered bicyclic ring), and CH2NHC(O)phenyl, wherein phenyl is optionally substituted one, two, or three times with halo, CO2H, or C1-C3 haloalkyl;
each R5 is independently selected from the group consisting of halo, OH, C1-C3 alkoxy, and NHC(O)C2-C3 alkenyl; and
R6 is H.

### Claim 20 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 21 (depends on 1)

A method of inhibiting the activity of EGFR in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of claim 1.

### Claim 22 (depends on 21)

The method of claim 21, wherein the EGFR is characterized by a mutation selected from the group consisting of L858R, T790M, and C797S, or any combination thereof.

### Claim 23 (depends on 1)

A method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of claim 1.

### Claim 24 (depends on 23)

The method of claim 23, wherein the cancer is selected from the group consisting of lung cancer, colon cancer, breast cancer, endometrial cancer, thyroid cancer, glioma, squamous cell carcinoma, and prostate cancer.

### Claim 25 (depends on 23)

The method according to claim 23, wherein the cancer is non-small cell lung cancer (NSCLC).
